Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia (Rituximab)

• ClinicalTrials.gov Identifier: NCT01230788
• Recruitment Status: Terminated
• First Posted: October 29, 2010
• Results First Posted: August 18, 2014
• Last Update Posted: December 1, 2014
• Sponsor: Emory University
• Information provided by (Responsible Party): Todd M. Cooper, Emory University

Study Description

Brief Summary:

This is a pilot study of a drug called rituximab used together with other drugs-prednisone, etoposide, and ifosfamide. Prednisone, etoposide, and ifosfamide have been used as part of standard chemotherapy for relapsed Acute Lymphoblastic Leukemia (ALL). Rituximab was approved by the Food and Drug Administration in 1997. However, the use of rituximab with prednisone, etoposide, and ifosfamide in pediatric patients with relapsed or refractory ALL is considered experimental.

This study is for patients who have ALL in second or greater relapse, or in first relapse and not responding to treatment.

The goals of this study are:

• To see if using rituximab with prednisone, etoposide, and ifosfamide is beneficial to leukemia treatment
• To find out what side effects this combination of drugs can cause

A total of 15 participants (30 years old or younger) will be enrolled, over a period of 2 years.

Condition or disease	Intervention/treatment	Phase
Leukemia; Acute Lymphoblastic Leukemia; ALL	Drug: rituximab	Not Applicable

Detailed Description:

Rationale for study design:

The combination of etoposide and ifosfamide is a reinduction regimen used in many previous studies for pediatric B lineage acute lymphoblastic leukemia (ALL). It does not use anthracyclines, and therefore can be safely used in patients at risk for cardiac toxicity due to previous anthracycline use.

Previous studies in adult patients with ALL have demonstrated safety and efficacy with the addition of rituximab to other induction regimens. Rituximab is an anti-CD20 monoclonal antibody. Approximately one-half of pediatric cases of B precursor ALL express the CD20 antigen on the leukemic blasts. The use of rituximab provides a potential target for CD20 positive cells, therefore improving the rates of cytotoxicity associated with the chemotherapy. Rituximab has been previously utilized in many pediatric and adult regimens in combination with other chemotherapeutic agents, and is expected to be safe with the combination of etoposide and ifosfamide. However, since it has never been studied with this combination of chemotherapy, strict stopping rules are in place to ensure that it is a safe combination.

A recent study demonstrated upregulation of CD20 expression on leukemic blasts exposed to one week of prednisone therapy. This increase in expression occurred in the majority of B-ALL patient samples, regardless of whether the patient initially expressed CD20 on the surface of the leukemic blasts. In those samples with upregulation of CD20 treated with rituximab, cytotoxicity from rituximab was more successful than in samples with a smaller percentage of CD20 expression.

Therefore, prednisone will be given for two weeks in combination with etoposide and ifosfamide. It is hoped that the percentage of leukemic blasts expressing CD20 will increase with this combination of medications, allowing the rituximab to be more effective when given weekly starting on day 8 of therapy. To better understand this process, samples of blood and bone marrow will be collected to quantify CD20 expression and the amount of leukemia present at multiple time points during the month of study duration.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 1 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Trial of Rituximab Combined With Prednisone/Ifosfamide/Etoposide for Relapsed Acute Lymphoblastic Leukemia (ALL)
• Study Start Date: September 2010
• Actual Primary Completion Date: October 2012
• Actual Study Completion Date: October 2012

Arms and Interventions

Arm	Intervention/treatment
Experimental: rituximab; study drug given	Drug: rituximab; 375 mg/m2/dose on days 8, 15, 22, and 29 (diluted in NS to a final concentration of 1 mg/ml for ease of administration). (Premedicate with Acetaminophen 15 mg/kg po (max 650 mg) and Diphenhydramine 1 mg/kg IV/PO (max 50 mg)).

Outcome Measures

Primary Outcome Measures :

1. 4 Month Event Free Survival (EFS) [ Time Frame: one year after enrollment ]
   To estimate the 4 month EFS after therapy with rituximab and cytotoxic chemotherapy (prednisone/etoposide/ifosfamide) in patients with second relapse/refractory ALL.
2. Toxicities of Rituximab [ Time Frame: two months after treatment ]
   To describe the toxicities of rituximab in addition to prednisone, etoposide, and ifosfamide.
3. Remission Induction Rate [ Time Frame: one month ]
   To estimate the remission induction rate of the addition of rituximab to cytotoxic chemotherapy (prednisone/etoposide/ifosfamide) in patients with second relapse/refractory ALL.

Secondary Outcome Measures :

1. Minimal Residual Disease [ Time Frame: one month after treatment ]
   To perform serial minimal residual disease (MRD) measurements to provide an objective determination of the effectiveness of this therapy.
2. Prednisone Effect [ Time Frame: one month after treatment ]
   To correlate the effect of prednisone on CD20 expression using serial measurements of CD20 expression in leukemic blasts.

Eligibility Criteria

• Ages Eligible for Study: 1 Year to 30 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Age: Patients must be 1-30 years of age at initial diagnosis.
2. Diagnosis: Patients must have histologically-confirmed relapsed/refractory Acute Lymphoblastic Leukemia (ALL).

3. Disease Status:Patients must be in

   • second or greater bone marrow relapse (≥ 25% blasts by morphology), or
   • refractory to reinduction therapy with one or more attempts at remission reinduction (end of reinduction blasts ≥ 5% by morphology and/or end of reinduction MRD ≥ 1% by flow cytometry).
   • Patients with combined bone marrow and extramedullary relapse are eligible (CNS 3 patients excluded).
4. Performance Status: Patients must have a performance status of ≥50 from the Lansky Scale if <10 years or ≥ 50 or from the Karnofsky Scale if ≥ 10 years. Patients who are unable to walk because of paralysis, but who are up in a wheelchair will be considered ambulatory for the purpose of assessing the performance score.

5. Prior Therapy: Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study and meet time restrictions from end of prior therapy as stated below:

   • Myelosuppressive chemotherapy: must not have received within 2 weeks of entry onto this study (4 weeks in the case of nitrosurea containing therapy). Patients who relapse while receiving ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this study. Cytoreduction with hydroxyurea can be initiated and continued for up to 24 hours prior to the start of therapy.
   • XRT: must be ≥ 4 weeks since the completion of radiation therapy.
   • Study specific limitations: must be ≥ 7 days since the completion of corticosteroid therapy.
   • Growth factor(s): Must not have received any hematopoietic growth factors (GCSF, Neulasta, or GMCSF) within 7 days of study entry.
   • Stem Cell Transplant: Patients must be at least two months from stem cell transplant, must be off immunosuppressives, and must have no evidence of active graft versus host disease.

   Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair.

6. Institutional review board approval.
7. Individual informed consent per local guidelines and federal and state regulations.

8. Organ Function: All patients must have adequate organ function defined as:

   • Renal Function: Patients must have a calculated creatinine clearance or radioisotope GFR ≥ 70mL/min/1.73m2 or a normal serum creatinine based on age/gender.
   • Liver Function: Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) for age, AND SGPT (ALT) ≤ 5 x institutional ULN for age
   • Cardiac Function: Ejection fraction > 50% on echocardiogram or MUGA Scan, OR Shortening fraction ≥ 27% on echocardiogram or MUGA Scan
   • Reproductive Function: Due to potential teratogenic effects of the drugs, all post-menarchal female patients must have a negative serum beta HCG prior to study enrollment. In addition, all patients of childbearing or child-fathering potential must agree to a medically acceptable form of contraception, including abstinence, while on study.

Exclusion Criteria:

1. Patients with an active and uncontrolled infection, defined as need for pressors, and/or positive cultures for 24 hours.
2. Patients recovering from allogeneic bone marrow transplantation who are still on immunosupressants.
3. Pregnant or lactating females. Women of childbearing age will agree to use contraception during the protocol.
4. Patients currently receiving other investigational agents, medications, or supplements with a known anti-leukemic effect.
5. Patients who, in the opinion of the investigator, will not be able to comply with safety monitoring requirements of the study.
6. Patients with reactivation of hepatitis B prior to starting therapy.
7. Patients who are HIV positive.
8. Patients must not have CNS 3 involvement.

Contacts and Locations

Locations

United States, Georgia

Children's Healthcare of Atlanta

Atlanta, Georgia, United States, 30322

Emory University

Atlanta, Georgia, United States, 30322

United States, Missouri

The children's Mercy Hospital

Kansas City, Missouri, United States, 64108

Sponsors and Collaborators

Emory University

Investigators

• Principal Investigator: Todd Cooper, DO; Emory University/Children's Healthcare of Atlanta

More Information

• Responsible Party: Todd M. Cooper, Assistant Professor, Emory University
• ClinicalTrials.gov Identifier: NCT01230788
• Other Study ID Numbers: IRB00039682; Rituximab ( Other Identifier: Other )
• First Posted: October 29, 2010
• Results First Posted: August 18, 2014
• Last Update Posted: December 1, 2014
• Last Verified: November 2014

Keywords provided by Todd M. Cooper, Emory University:

ALL; Leukemia; Rituximab; Pediatrics

Additional relevant MeSH terms:

Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphoid; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Rituximab; Antineoplastic Agents, Immunological; Antineoplastic Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents